These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 34663928)
21. Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells. Maria ATJ; Toupet K; Maumus M; Rozier P; Vozenin MC; Le Quellec A; Jorgensen C; Noël D; Guilpain P Front Immunol; 2018; 9():2571. PubMed ID: 30455706 [No Abstract] [Full Text] [Related]
22. iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis. Maria ATJ; Rozier P; Fonteneau G; Sutra T; Maumus M; Toupet K; Cristol JP; Jorgensen C; Guilpain P; Noël D Front Immunol; 2018; 9():3056. PubMed ID: 30622540 [No Abstract] [Full Text] [Related]
23. The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation. Servaas NH; Spierings J; Pandit A; van Laar JM Clin Exp Immunol; 2020 Jul; 201(1):34-39. PubMed ID: 31990046 [TBL] [Abstract][Full Text] [Related]
24. Immunomodulatory therapy for SSc: will high-intensity immunosuppression with stem cell rescue improve outcome? Crofford LJ Curr Rheumatol Rep; 2005 Apr; 7(2):142-9. PubMed ID: 15760594 [TBL] [Abstract][Full Text] [Related]
25. [Autologous hematopoietic stem cell transplantation for systemic sclerosis : Position statement of the stem cell therapy working party of the German Society of Rheumatology]. Alexander T; Henes J; Distler JHW; Schmalzing M; Blank N; Kötter I; Hiepe F Z Rheumatol; 2020 Jun; 79(5):429-436. PubMed ID: 32322977 [TBL] [Abstract][Full Text] [Related]
26. Case report: A successful second autologous hematopoietic stem cell transplantation in refractory systemic sclerosis, with positive effect on skin involvement, pulmonary function and microcirculation. Haverkort DA; Kersten BE; van Rhenen A; van der Velden WJFM; Vonk MC Front Immunol; 2022; 13():925776. PubMed ID: 36505455 [TBL] [Abstract][Full Text] [Related]
28. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. Zhao M; Wu J; Wu H; Sawalha AH; Lu Q Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302 [TBL] [Abstract][Full Text] [Related]
29. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Distler O; Volkmann ER; Hoffmann-Vold AM; Maher TM Expert Rev Clin Immunol; 2019 Oct; 15(10):1009-1017. PubMed ID: 31566449 [No Abstract] [Full Text] [Related]
30. [Interests and potentials of adipose tissue in scleroderma]. Daumas A; Eraud J; Hautier A; Sabatier F; Magalon G; Granel B Rev Med Interne; 2013 Dec; 34(12):763-9. PubMed ID: 24050783 [TBL] [Abstract][Full Text] [Related]
31. Regenerative treatments for scleroderma in cutaneous manifestations of the face: a systematic review. Schipper JAM; Verhoef LL; Schepers RH; Dijkstra PU; Stel AJ; van der Werf S; Mulder DJ; Harmsen MC; Jansma J Clin Exp Rheumatol; 2024 Aug; 42(8):1675-1689. PubMed ID: 38976297 [TBL] [Abstract][Full Text] [Related]
32. Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine. Griffin M; Ryan CM; Pathan O; Abraham D; Denton CP; Butler PE Stem Cell Res Ther; 2017 Feb; 8(1):23. PubMed ID: 28173869 [TBL] [Abstract][Full Text] [Related]
33. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells. Ra JC; Kang SK; Shin IS; Park HG; Joo SA; Kim JG; Kang BC; Lee YS; Nakama K; Piao M; Sohl B; Kurtz A J Transl Med; 2011 Oct; 9():181. PubMed ID: 22017805 [TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Cipriani P; Di Benedetto P; Liakouli V; Del Papa B; Di Padova M; Di Ianni M; Marrelli A; Alesse E; Giacomelli R Clin Exp Immunol; 2013 Aug; 173(2):195-206. PubMed ID: 23607751 [TBL] [Abstract][Full Text] [Related]
35. Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis. Del Papa N; Pignataro F; Zaccara E; Maglione W; Minniti A Front Immunol; 2018; 9():2390. PubMed ID: 30386340 [TBL] [Abstract][Full Text] [Related]
36. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Rosen O; Massenkeil G; Hiepe F; Pest S; Hauptmann S; Radtke H; Burmester G; Thiel A; Radbruch A; Heymer B; Arnold R Bone Marrow Transplant; 2001 Mar; 27(6):657-8. PubMed ID: 11319598 [TBL] [Abstract][Full Text] [Related]
37. Cellular therapy of systemic sclerosis. van Laar JM; Tyndall A Curr Rheumatol Rep; 2008 Jul; 10(3):189-94. PubMed ID: 18638426 [TBL] [Abstract][Full Text] [Related]